Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

The safety and efficacy of psilocybin as an adjunctive therapy in participants with treatment-resistant depression

To see complete record on, please visit this link

Id: 2018-002577-22

Organisation Name: COMPASS Pathfinder, Limited

Start Date: 2019-12-20

Completion Date: Restarted

Brief Summary: The primary objective of this study is to explore the efficacy of 25 mg psilocybin as an adjunct therapy to antidepressants in improving depressive symptoms.

Country: United Kingdom

Total execution time in seconds: 0.095585823059082